Key clinical point:
Major finding: In total, 58% of patients who switched to nilotinib experienced treatment-free remission at 48 weeks.
Study details: A single-group, open-label phase 2 study.
Disclosures: Novartis Pharmaceuticals funded the study. The researchers reported financial ties to Novartis and other pharmaceutical companies.
Source: Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.
Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.
This Week's Must Reads
BTK inhibitor shows phase 1 results in Waldenstrom’s macroglobulinemia, Leukemia & Lymphoma 2018
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.
Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.
The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018
Must Reads in CML
Treatment-free remission in CML, Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.
Bosulif Approved to Treat Newly-Diagnosed Ph+ CML, Avillion news release; 2017 Dec 19
Sprycel Approved for Children with Ph+ CML, FDA news release; 2017 Nov 9
Be Sure to Consider This When Selecting TKIs, Clin Lymphoma Myeloma Leuk; ePub 2017 Jun 16; Coutinho, et al
FDA Approves Iclusig for Certain Types of CML, ALL, Ariad news release; 2016 Nov 29